Ramin Tadayoni Award 2025: Oculis Holding AG, in collaboration with EURETINA, announced Dr. Prithvi Ramtohul as the winner of the Ramin Tadayoni Award for his contributions to retinal imaging and diseases, particularly focusing on neuronal excitability in retinal ganglion cells.
Oculis' Commitment to Retinal Research: Oculis emphasizes its dedication to advancing retinal research and honoring the legacy of Professor Ramin Tadayoni, while also highlighting its innovative pipeline of ophthalmic treatments aimed at addressing significant unmet medical needs.
OCS
$19.84+Infinity%1D
Analyst Views on OCS
Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 39.50 USD with a low forecast of 29.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast OCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OCS is 39.50 USD with a low forecast of 29.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.470
Low
29.00
Averages
39.50
High
51.00
Current: 20.470
Low
29.00
Averages
39.50
High
51.00
BofA
Buy
maintain
$30 -> $29
2025-11-13
Reason
BofA
Price Target
$30 -> $29
2025-11-13
maintain
Buy
Reason
BofA lowered the firm's price target on Oculis to $29 from $30 and keeps a Buy rating on the shares after the company reported Q3 results. The firm, which now incorporates the October equity financing in its model, exits Q3 reiterating its view that Oculis's assets are "underappreciated."
H.C. Wainwright
Yi Chen
Buy
maintain
$36 -> $42
2025-11-11
Reason
H.C. Wainwright
Yi Chen
Price Target
$36 -> $42
2025-11-11
maintain
Buy
Reason
H.C. Wainwright analyst Yi Chen raised the firm's price target on Oculis to $42 from $36 and keeps a Buy rating on the shares following the Q3 report. The firm says the company's PIONEER registrational program targets an untapped market opportunity of over $7B.
Needham
NULL
to
Buy
initiated
$36
2025-08-27
Reason
Needham
Price Target
$36
2025-08-27
initiated
NULL
to
Buy
Reason
Needham initiated coverage of Oculis with a Buy rating and $36 price target. Lead-asset OCS-01 aims to be the first non-invasive therapy for diabetic macular edema, while OCS-02 offers a biologic mechanism of action for dry-eye disease via eye drop, notes the analyst, who calls Oculis "an under-the-radar story nearing a data-rich period in early-2026."
H.C. Wainwright
Buy
maintain
$32 -> $33
2025-08-22
Reason
H.C. Wainwright
Price Target
$32 -> $33
2025-08-22
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Oculis to $33 from $32 and keeps a Buy rating on the shares following the Q2 report.
About OCS
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
